Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193388 | 1.00 | CACNA1B (0.50) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL193387 | 1.00 | CACNA1B (0.50) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL192376 | 0.92 | CACNA1B (0.52) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL192377 | 0.92 | CACNA1B (0.52) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL376031 | 0.92 | CACNA1B (0.52) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL2064232 | 0.91 | CACNA1B (0.51) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL2063543 | 0.91 | CACNA1B (0.51) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL192830 | 0.89 | HDAC4 (0.49) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL192829 | 0.89 | HDAC4 (0.49) | CACNA1BHDAC4HDAC1HDAC6CTSK | |
| SCHEMBL30022028 | 0.88 | CTSK (0.56) | CACNA1BHDAC4HDAC1HDAC6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| EP-1877383-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | CACNA1B 3713/4885HDAC4 1741/4885HDAC1 423/4885 |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | CACNA1B 4712/4885HDAC4 2850/4885HDAC1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.